Hexarelin
Hexarelin Acetate (5mg)
$130USD
Third-Party Tested
Independent lab verified
Batch-Specific CoA
Publicly accessible
YPB.261
Reference number
5mg
Lyophilized vial
Synthetic hexapeptide GHRP. Potent GH secretagogue with additional cardioprotective activity observed in preclinical studies.
Origin
Hexarelin was developed in the early 1990s by Romano Deghenghi at Europeptides as a structural analog of GHRP-6 with enhanced potency. It was designed through systematic substitution of the D-Trp and Trp residues in the GHRP-6 scaffold with 2-methyltryptophan derivatives.
Research Lineage
Ghigo et al. at the University of Turin conducted extensive clinical pharmacology studies on Hexarelin throughout the 1990s. Bhatt et al. and Bisi et al. characterized its effects on GH secretion across age groups. Uniquely, Locatelli and colleagues discovered its binding to the CD36 scavenger receptor, opening a separate line of cardiovascular research.
Mechanism of Action
Hexarelin activates the GHS-R1a receptor with higher binding affinity than GHRP-6. It also binds to the CD36 receptor on cardiomyocytes, an interaction unrelated to GH secretion that has been studied in cardiac ischemia and atherosclerosis models. Like other GHRPs, it stimulates GH release synergistically with GHRH.
Structural Notes
Hexapeptide. Sequence: His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH2. Molecular weight: 887.04 Da.
Key References
Ghigo E et al. J Clin Endocrinol Metab. 1994;79(1):1-6.
Locatelli V et al. Ann Med. 2002;34(2):102-8.
Research Use Only. This product is intended for laboratory research purposes only. Not for human or veterinary use. Not for sale to minors.